PURPOSE: The chronic respiratory diseases may combine pulmonary hypertension and it makes the poor prognostic factor. Therefore we evaluate pulmonary hypertension by regular echocardiography in Osaka City General Hospital.
METHODS: In echocardiography findings conducted by June, 2007 from August, 2010, eight chronic respiratory disease patients took bosentan for estimated pulmonary systolic pressure more than 37mmHg. We checked the administration effect (WHO functional class, Pro-BNP level or BNP level, and systolic pulmonary arterial pressure by echocardiography ).
RESULTS: Target patients are 6 men and 2 women. Target for chronic respiratory diseases are 4 IPF, 3 COPD,and 1 Sarcoidosis. WHO functional class III/IV is 3/5, Pro-BNP level is 4662 ± 4613 pg/ml (BNP level is 850 ± 290 pg/ml), and systolic pulmonary arterial pressure by echocardiography is 69.5 ± 21.5mmHg. Oxygen therapy was provided in all cases before bosentan administration. One patient discontinued the medication for headache exacerbation after administration. And One patient died 41 days after bosentan administration. The other cases showed a decrease at Pro-BNP level or BNP level in all cases. Six patients had a decrease at systolic pulmonary arterial pressure by echocardiography. Three patients had improvement at the WHO functional class.
CONCLUSIONS: We found the effective result for bosentan administration to chronic respiratory disease with secondary pulmonary hypertension.
CLINICAL IMPLICATIONS: Bosentan may show efficacy for secondary pulmonary hypertension.
DISCLOSURE: The following authors have nothing to disclose: Mitsuhiro Sumitani, Natsuko Miyamoto, Masayoshi Nishijima, Seiichi Shoji
No Product/Research Disclosure Information